logo
Share SHARE
FONT-SIZE Plus   Neg

Merck Announces New Phase III Data For Suvorexant - Quick Facts

Merck & Co. Inc. (MRK) announced the new Phase III Data for suvorexant, the investigational medicine the compoany is developing for the treatment of insomnia.

The 12-month study was designed to assess the safety of suvorexant, while also evaluating its longer term efficacy. The company said it presented new results from a two-month discontinuation phase that followed the 12-month study at the 21st Congress of the European Sleep Research Society or ESRS.

The company said that the results from the two-month discontinuation phase showed that, after daily use of a consistent dose of suvorexant for one year, patients who stopped taking the medicine experienced a return of their sleeping difficulties to levels similar to those reported by patients who received placebo over the course of the trial.

The company noted that Patients who continued to receive suvorexant for the additional two months experienced mean improvements in their ability to fall asleep and stay asleep that were consistent with those seen over the first 12 months compared to placebo. Adverse experiences reported in the two-month discontinuation phase were generally consistent with those reported during the 12-month study.

The company stated that it plans to file a New Drug Application (NDA) for suvorexant with the U.S. Food and Drug Administration or FDA in 2012. If approved, suvorexant would be the first in a new class of medicines, called orexin receptor antagonists, for use in patients with difficulty falling or staying asleep. The company said it anticipates that suvorexant will be evaluated by the Controlled Substance Staff of the FDA.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Bank of Nova Scotia or otherwise known as Scotiabank, Friday reported lower net profit for the third quarter, in the absence of a year-ago gain. Earnings per share, however, came in line with the Street view. Further, the company said it raised its quarterly dividend by 2 cents. Non-traditional discount and variety stores operator Big Lots Inc. (BIG) Friday reported a decline in net profit for the second quarter, while net sales grew 1.2 percent from the prior year. Comparable sales for the quarter increased 2.8 percent. Google has rejected the European Union's charges that it abused its market power and the demanded that it change the way it ranks online comparison shopping services in its search results, setting up a potentially long legal battle with the EU regulator empowered to levy billions of euros in fines
comments powered by Disqus
RELATED NEWS
Trade MRK now with 
Follow RTT